In this large real-world analysis of adults with type 2 diabetes, initiation of canagliflozin was associated with a higher risk of MACE and all-cause mortality compared to initiation of a selective SGLT2 inhibitor. Here, SLC5A2 is linked to type 2 diabetes mellitus.